Review



anti mouse ifn l 2 3 antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems anti mouse ifn l 2 3 antibody
    (A) Experimental schematic depicting isotype control (Iso) and <t>a-IFN-L</t> blocking antibody treatment (a-IFN-L) following progesterone administration in SPF or GF mice. (B) Quantification of uterine type 17 lymphoid cells shown as fold change in absolute cell number in progesterone treated SPF animals treated with a-IFN-L relative to Iso treated animals. (C, D) Quantification of absolute cell number of uterine (C) RORγT + γδT cells and (D) Th17 cells. (E) Experimental schematic showing progesterone treatment of wild type (WT) littermate control or IFN-L receptor (IFNLR) knock out mice, followed by sorting of EpCam + and CD45 + cells for single cell RNA sequencing. (F) UMAP projection showing uterine cells sorted using an EpCam gate. (G) Expression of the ISGs Ifi27l2a, Irf7, Isg15, Oas2, Oasl2 across EpCam + clusters from WT and IFNLR KO mice. (H) Volcano plot displaying differentially expressed genes from uterine luminal epithelial cells. (I) Top enriched GO term pathways for genes downregulated in uterine luminal epithelial cells from IFNLR KO mice, with Log 2 fold change values shown for differentially expressed genes in each highlighted pathway. (J) Working model. (B-D) Each dot represents an individual tissue from three biological replicates with mean with ± SEM. Significance determined by an unpaired Student’s t-test. * denote p-val <0.05 ** denote p-val <0.01.
    Anti Mouse Ifn L 2 3 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ifn+b/Mouse+IL-28A%2FB+(IFN-lambda+2%2F3)+Antibody/bio_rxiv__64898__2026__01__27__701820-204-9-13
    Average 94 stars, based on 15 article reviews
    anti mouse ifn l 2 3 antibody - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "Microbiota-dependent IFN-L controls uterine and placental immunity"

    Article Title: Microbiota-dependent IFN-L controls uterine and placental immunity

    Journal: bioRxiv

    doi: 10.64898/2026.01.27.701820

    (A) Experimental schematic depicting isotype control (Iso) and a-IFN-L blocking antibody treatment (a-IFN-L) following progesterone administration in SPF or GF mice. (B) Quantification of uterine type 17 lymphoid cells shown as fold change in absolute cell number in progesterone treated SPF animals treated with a-IFN-L relative to Iso treated animals. (C, D) Quantification of absolute cell number of uterine (C) RORγT + γδT cells and (D) Th17 cells. (E) Experimental schematic showing progesterone treatment of wild type (WT) littermate control or IFN-L receptor (IFNLR) knock out mice, followed by sorting of EpCam + and CD45 + cells for single cell RNA sequencing. (F) UMAP projection showing uterine cells sorted using an EpCam gate. (G) Expression of the ISGs Ifi27l2a, Irf7, Isg15, Oas2, Oasl2 across EpCam + clusters from WT and IFNLR KO mice. (H) Volcano plot displaying differentially expressed genes from uterine luminal epithelial cells. (I) Top enriched GO term pathways for genes downregulated in uterine luminal epithelial cells from IFNLR KO mice, with Log 2 fold change values shown for differentially expressed genes in each highlighted pathway. (J) Working model. (B-D) Each dot represents an individual tissue from three biological replicates with mean with ± SEM. Significance determined by an unpaired Student’s t-test. * denote p-val <0.05 ** denote p-val <0.01.
    Figure Legend Snippet: (A) Experimental schematic depicting isotype control (Iso) and a-IFN-L blocking antibody treatment (a-IFN-L) following progesterone administration in SPF or GF mice. (B) Quantification of uterine type 17 lymphoid cells shown as fold change in absolute cell number in progesterone treated SPF animals treated with a-IFN-L relative to Iso treated animals. (C, D) Quantification of absolute cell number of uterine (C) RORγT + γδT cells and (D) Th17 cells. (E) Experimental schematic showing progesterone treatment of wild type (WT) littermate control or IFN-L receptor (IFNLR) knock out mice, followed by sorting of EpCam + and CD45 + cells for single cell RNA sequencing. (F) UMAP projection showing uterine cells sorted using an EpCam gate. (G) Expression of the ISGs Ifi27l2a, Irf7, Isg15, Oas2, Oasl2 across EpCam + clusters from WT and IFNLR KO mice. (H) Volcano plot displaying differentially expressed genes from uterine luminal epithelial cells. (I) Top enriched GO term pathways for genes downregulated in uterine luminal epithelial cells from IFNLR KO mice, with Log 2 fold change values shown for differentially expressed genes in each highlighted pathway. (J) Working model. (B-D) Each dot represents an individual tissue from three biological replicates with mean with ± SEM. Significance determined by an unpaired Student’s t-test. * denote p-val <0.05 ** denote p-val <0.01.

    Techniques Used: Control, Blocking Assay, Knock-Out, RNA Sequencing, Expressing

    (A) Quantification of uterine ILC3 absolute cell number in SPF and GF animals treated with progesterone and Iso or a-IFN-L. Each dot represents an individual tissue from three biological replicates with mean ± SEM. Significance was determined by an unpaired Student’s t-test. (B) UMAP projection of CD45 + cells sorted from WT and IFNLR KO uteri. (C) Dot plot showing expression of Ifnar1 or Ifnlr in WT cells from the EpCam + and CD45 + library. (D, E) Dot plot showing marker gene expression for each cell type from the (D) EpCam + or (E) CD45 + library.
    Figure Legend Snippet: (A) Quantification of uterine ILC3 absolute cell number in SPF and GF animals treated with progesterone and Iso or a-IFN-L. Each dot represents an individual tissue from three biological replicates with mean ± SEM. Significance was determined by an unpaired Student’s t-test. (B) UMAP projection of CD45 + cells sorted from WT and IFNLR KO uteri. (C) Dot plot showing expression of Ifnar1 or Ifnlr in WT cells from the EpCam + and CD45 + library. (D, E) Dot plot showing marker gene expression for each cell type from the (D) EpCam + or (E) CD45 + library.

    Techniques Used: Expressing, Marker, Gene Expression

    (A) Experimental schematic showing Iso or a-IFN-L treatment before and throughout intravaginal GBS colonization of nulliparous animals. (B-D) Quantification of GBS counts in (B) vaginal lavages from 1-6 dpa, (C) vaginal and (D) uterine tissue at 6 dpa. (E) Experimental schematic showing Iso or a-IFN-L treatment before and throughout intravaginal GBS infection of timed pregnant dams. (F) Number of implantation sites per litter in Iso or a-IFN-L treated GBS-infected pregnant dams. (G) Quantification of the fetus-to-placenta weight ratio in Iso or a-IFN-L treated GBS-infected pregnant dams at gd16.5. (H) Quantification of GBS counts in indicated tissues at 3 dpi. (I) Quantification of GBS counts in fetal liver at 3 dpi. (J) Graphical representation of fetal outcomes found in mock or GBS-infected Iso or a-IFN-L treated pregnant dams at gd16.5. (K) Working model. (B) Significance was determined by two-way ANOVA with Tukey’s multiple comparison test with mean ± SEM from three biological replicates. (C, D, G, H, I) Each dot represents an individual tissue from at least three biological replicates with mean ± SEM. (F) Each dot represents the total number of implantation sites per individual dam from at least three biological replicates with mean ± SEM. (C, D, F-I) Significance determined by an unpaired Student’s t-test. *** denote p-val<0.001, **** denote p-val<0.0001.
    Figure Legend Snippet: (A) Experimental schematic showing Iso or a-IFN-L treatment before and throughout intravaginal GBS colonization of nulliparous animals. (B-D) Quantification of GBS counts in (B) vaginal lavages from 1-6 dpa, (C) vaginal and (D) uterine tissue at 6 dpa. (E) Experimental schematic showing Iso or a-IFN-L treatment before and throughout intravaginal GBS infection of timed pregnant dams. (F) Number of implantation sites per litter in Iso or a-IFN-L treated GBS-infected pregnant dams. (G) Quantification of the fetus-to-placenta weight ratio in Iso or a-IFN-L treated GBS-infected pregnant dams at gd16.5. (H) Quantification of GBS counts in indicated tissues at 3 dpi. (I) Quantification of GBS counts in fetal liver at 3 dpi. (J) Graphical representation of fetal outcomes found in mock or GBS-infected Iso or a-IFN-L treated pregnant dams at gd16.5. (K) Working model. (B) Significance was determined by two-way ANOVA with Tukey’s multiple comparison test with mean ± SEM from three biological replicates. (C, D, G, H, I) Each dot represents an individual tissue from at least three biological replicates with mean ± SEM. (F) Each dot represents the total number of implantation sites per individual dam from at least three biological replicates with mean ± SEM. (C, D, F-I) Significance determined by an unpaired Student’s t-test. *** denote p-val<0.001, **** denote p-val<0.0001.

    Techniques Used: Infection, Comparison

    (A) Experimental schematic showing Iso or a-IFN-L neutralizing antibody treatment before and throughout intravaginal GBS infection of timed pregnant dams. Maternal and neonatal outcomes were monitored through perinatal day 11. (B) Survival curve displaying maternal survival following GBS infection during pregnancy and through the first 11 days of the perinatal period. (C) Quantification of vaginal GBS burden in dams at perinatal day 11. (D) Quantification of litter size per individual dam at postnatal day 5. (E) Quantification of neonatal weight at postnatal day 5, 9 and 11. (F) Quantification of GBS CFU/mL in the neonatal liver, lung, brain, and intestine at postnatal day 11. Each dot represents an individual tissue with mean ± SEM. (G) Proportion of neonatal livers, lungs, brains, and intestines positive for GBS at postnatal day 11. (B-G) Three independent replicates were performed. (B) A log-rank test was performed to determine statistical significance. (C, F, G) An unpaired Student’s t-test was performed to determine statistical significance. (D) A one-way ANOVA with multiple comparisons was performed to determine statistical significance. (E) A two-way ANOVA with multiple comparisons was performed to determine statistical significance. *denote p-val <0.05.
    Figure Legend Snippet: (A) Experimental schematic showing Iso or a-IFN-L neutralizing antibody treatment before and throughout intravaginal GBS infection of timed pregnant dams. Maternal and neonatal outcomes were monitored through perinatal day 11. (B) Survival curve displaying maternal survival following GBS infection during pregnancy and through the first 11 days of the perinatal period. (C) Quantification of vaginal GBS burden in dams at perinatal day 11. (D) Quantification of litter size per individual dam at postnatal day 5. (E) Quantification of neonatal weight at postnatal day 5, 9 and 11. (F) Quantification of GBS CFU/mL in the neonatal liver, lung, brain, and intestine at postnatal day 11. Each dot represents an individual tissue with mean ± SEM. (G) Proportion of neonatal livers, lungs, brains, and intestines positive for GBS at postnatal day 11. (B-G) Three independent replicates were performed. (B) A log-rank test was performed to determine statistical significance. (C, F, G) An unpaired Student’s t-test was performed to determine statistical significance. (D) A one-way ANOVA with multiple comparisons was performed to determine statistical significance. (E) A two-way ANOVA with multiple comparisons was performed to determine statistical significance. *denote p-val <0.05.

    Techniques Used: Infection



    Similar Products

    90
    PBL Assay ifn-b elisa kit
    Ifn B Elisa Kit, supplied by PBL Assay, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ifn+b/ifn+%CE%B2+elisa+kit/pmc09931548__mmc3-291-17-21
    Average 90 stars, based on 1 article reviews
    ifn-b elisa kit - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    97
    PBL Assay human interferon beta 1a
    Human Interferon Beta 1a, supplied by PBL Assay, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ifn+b/Human+Interferon+Beta+1a/custom%4011410-2%4042455875
    Average 97 stars, based on 1 article reviews
    human interferon beta 1a - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    94
    Sino Biological biotinylated antihuman ifn γ antibody
    Biotinylated Antihuman Ifn γ Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ifn+b/Interferon+Gamma%2FIFN+gamma%2FIFNG+Antibody+(Biotin)%2C+Rabbit+MAb/pm41666293-45-6-43
    Average 94 stars, based on 1 article reviews
    biotinylated antihuman ifn γ antibody - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    Sino Biological biotinylated anti human ifn γ antibody
    (a) Schematic of laser-cut PDMS microwell array reversibly assembled on a polystyrene petri dish and workflow of enzymatically amplified silver metallization using Biotin-BSA and poly-HRP-SA. (b) Cell-phone image of silver metallized wells after assay. (c) Biotin-BSA dilution curve obtained from cell-phone image silver darkness quantification in ImageJ. (d) Assay stack for initial biotinyl tyramide signal amplification testing using <t>biotinylated</t> <t>anti-IFN-γ</t> as capture. (e) Dilution curve of silver darkness of increasing biotinylated anti-IFN-γ as target and 10 µg/mL, 1 µg/mL, and 0 µg/mL biotinyl tyramide. All assays were repeated three (n=3) times and fit lines are four-parameter logistic sigmoidal curves.
    Biotinylated Anti Human Ifn γ Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ifn+b/Interferon+Gamma%2FIFN+gamma%2FIFNG+Antibody+(Biotin)%2C+Rabbit+MAb/bio_rxiv__64898__2026__01__27__700981-14-5-37
    Average 94 stars, based on 1 article reviews
    biotinylated anti human ifn γ antibody - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    R&D Systems anti mouse ifn l 2 3 antibody
    (A) Experimental schematic depicting isotype control (Iso) and <t>a-IFN-L</t> blocking antibody treatment (a-IFN-L) following progesterone administration in SPF or GF mice. (B) Quantification of uterine type 17 lymphoid cells shown as fold change in absolute cell number in progesterone treated SPF animals treated with a-IFN-L relative to Iso treated animals. (C, D) Quantification of absolute cell number of uterine (C) RORγT + γδT cells and (D) Th17 cells. (E) Experimental schematic showing progesterone treatment of wild type (WT) littermate control or IFN-L receptor (IFNLR) knock out mice, followed by sorting of EpCam + and CD45 + cells for single cell RNA sequencing. (F) UMAP projection showing uterine cells sorted using an EpCam gate. (G) Expression of the ISGs Ifi27l2a, Irf7, Isg15, Oas2, Oasl2 across EpCam + clusters from WT and IFNLR KO mice. (H) Volcano plot displaying differentially expressed genes from uterine luminal epithelial cells. (I) Top enriched GO term pathways for genes downregulated in uterine luminal epithelial cells from IFNLR KO mice, with Log 2 fold change values shown for differentially expressed genes in each highlighted pathway. (J) Working model. (B-D) Each dot represents an individual tissue from three biological replicates with mean with ± SEM. Significance determined by an unpaired Student’s t-test. * denote p-val <0.05 ** denote p-val <0.01.
    Anti Mouse Ifn L 2 3 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ifn+b/Mouse+IL-28A%2FB+(IFN-lambda+2%2F3)+Antibody/bio_rxiv__64898__2026__01__27__701820-204-9-13
    Average 94 stars, based on 1 article reviews
    anti mouse ifn l 2 3 antibody - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    PBL Assay verikine-hs human ifn beta elisa kit
    (A) Experimental schematic depicting isotype control (Iso) and <t>a-IFN-L</t> blocking antibody treatment (a-IFN-L) following progesterone administration in SPF or GF mice. (B) Quantification of uterine type 17 lymphoid cells shown as fold change in absolute cell number in progesterone treated SPF animals treated with a-IFN-L relative to Iso treated animals. (C, D) Quantification of absolute cell number of uterine (C) RORγT + γδT cells and (D) Th17 cells. (E) Experimental schematic showing progesterone treatment of wild type (WT) littermate control or IFN-L receptor (IFNLR) knock out mice, followed by sorting of EpCam + and CD45 + cells for single cell RNA sequencing. (F) UMAP projection showing uterine cells sorted using an EpCam gate. (G) Expression of the ISGs Ifi27l2a, Irf7, Isg15, Oas2, Oasl2 across EpCam + clusters from WT and IFNLR KO mice. (H) Volcano plot displaying differentially expressed genes from uterine luminal epithelial cells. (I) Top enriched GO term pathways for genes downregulated in uterine luminal epithelial cells from IFNLR KO mice, with Log 2 fold change values shown for differentially expressed genes in each highlighted pathway. (J) Working model. (B-D) Each dot represents an individual tissue from three biological replicates with mean with ± SEM. Significance determined by an unpaired Student’s t-test. * denote p-val <0.05 ** denote p-val <0.01.
    Verikine Hs Human Ifn Beta Elisa Kit, supplied by PBL Assay, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ifn+b/VeriKine-HS+Human+IFN+Beta+ELISA+Kit/custom%4041415-1%4041159953
    Average 94 stars, based on 1 article reviews
    verikine-hs human ifn beta elisa kit - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    96
    R&D Systems granzyme b concentrations
    (A) Experimental schematic depicting isotype control (Iso) and <t>a-IFN-L</t> blocking antibody treatment (a-IFN-L) following progesterone administration in SPF or GF mice. (B) Quantification of uterine type 17 lymphoid cells shown as fold change in absolute cell number in progesterone treated SPF animals treated with a-IFN-L relative to Iso treated animals. (C, D) Quantification of absolute cell number of uterine (C) RORγT + γδT cells and (D) Th17 cells. (E) Experimental schematic showing progesterone treatment of wild type (WT) littermate control or IFN-L receptor (IFNLR) knock out mice, followed by sorting of EpCam + and CD45 + cells for single cell RNA sequencing. (F) UMAP projection showing uterine cells sorted using an EpCam gate. (G) Expression of the ISGs Ifi27l2a, Irf7, Isg15, Oas2, Oasl2 across EpCam + clusters from WT and IFNLR KO mice. (H) Volcano plot displaying differentially expressed genes from uterine luminal epithelial cells. (I) Top enriched GO term pathways for genes downregulated in uterine luminal epithelial cells from IFNLR KO mice, with Log 2 fold change values shown for differentially expressed genes in each highlighted pathway. (J) Working model. (B-D) Each dot represents an individual tissue from three biological replicates with mean with ± SEM. Significance determined by an unpaired Student’s t-test. * denote p-val <0.05 ** denote p-val <0.01.
    Granzyme B Concentrations, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ifn+b/Human+IFN-gamma+DuoSet+ELISA/bio_rxiv__2025__09__07__674706-305-10-17
    Average 96 stars, based on 1 article reviews
    granzyme b concentrations - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    R&D Systems dif50c human granzyme b elisa kit r d systems
    (A) Experimental schematic depicting isotype control (Iso) and <t>a-IFN-L</t> blocking antibody treatment (a-IFN-L) following progesterone administration in SPF or GF mice. (B) Quantification of uterine type 17 lymphoid cells shown as fold change in absolute cell number in progesterone treated SPF animals treated with a-IFN-L relative to Iso treated animals. (C, D) Quantification of absolute cell number of uterine (C) RORγT + γδT cells and (D) Th17 cells. (E) Experimental schematic showing progesterone treatment of wild type (WT) littermate control or IFN-L receptor (IFNLR) knock out mice, followed by sorting of EpCam + and CD45 + cells for single cell RNA sequencing. (F) UMAP projection showing uterine cells sorted using an EpCam gate. (G) Expression of the ISGs Ifi27l2a, Irf7, Isg15, Oas2, Oasl2 across EpCam + clusters from WT and IFNLR KO mice. (H) Volcano plot displaying differentially expressed genes from uterine luminal epithelial cells. (I) Top enriched GO term pathways for genes downregulated in uterine luminal epithelial cells from IFNLR KO mice, with Log 2 fold change values shown for differentially expressed genes in each highlighted pathway. (J) Working model. (B-D) Each dot represents an individual tissue from three biological replicates with mean with ± SEM. Significance determined by an unpaired Student’s t-test. * denote p-val <0.05 ** denote p-val <0.01.
    Dif50c Human Granzyme B Elisa Kit R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ifn+b/Human+IFN-gamma+Quantikine+ELISA+Kit/pmc12281382__mmc2-260-155-161
    Average 96 stars, based on 1 article reviews
    dif50c human granzyme b elisa kit r d systems - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    97
    R&D Systems mouse ifn b duoset elisa kit
    (A) Experimental schematic depicting isotype control (Iso) and <t>a-IFN-L</t> blocking antibody treatment (a-IFN-L) following progesterone administration in SPF or GF mice. (B) Quantification of uterine type 17 lymphoid cells shown as fold change in absolute cell number in progesterone treated SPF animals treated with a-IFN-L relative to Iso treated animals. (C, D) Quantification of absolute cell number of uterine (C) RORγT + γδT cells and (D) Th17 cells. (E) Experimental schematic showing progesterone treatment of wild type (WT) littermate control or IFN-L receptor (IFNLR) knock out mice, followed by sorting of EpCam + and CD45 + cells for single cell RNA sequencing. (F) UMAP projection showing uterine cells sorted using an EpCam gate. (G) Expression of the ISGs Ifi27l2a, Irf7, Isg15, Oas2, Oasl2 across EpCam + clusters from WT and IFNLR KO mice. (H) Volcano plot displaying differentially expressed genes from uterine luminal epithelial cells. (I) Top enriched GO term pathways for genes downregulated in uterine luminal epithelial cells from IFNLR KO mice, with Log 2 fold change values shown for differentially expressed genes in each highlighted pathway. (J) Working model. (B-D) Each dot represents an individual tissue from three biological replicates with mean with ± SEM. Significance determined by an unpaired Student’s t-test. * denote p-val <0.05 ** denote p-val <0.01.
    Mouse Ifn B Duoset Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ifn+b/Mouse+IL-6+DuoSet+ELISA/pmc10629565__pnas__2214320120__sapp-19-8-13
    Average 97 stars, based on 1 article reviews
    mouse ifn b duoset elisa kit - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    90
    ImmunoTools ifn-a/b
    (A) Experimental schematic depicting isotype control (Iso) and <t>a-IFN-L</t> blocking antibody treatment (a-IFN-L) following progesterone administration in SPF or GF mice. (B) Quantification of uterine type 17 lymphoid cells shown as fold change in absolute cell number in progesterone treated SPF animals treated with a-IFN-L relative to Iso treated animals. (C, D) Quantification of absolute cell number of uterine (C) RORγT + γδT cells and (D) Th17 cells. (E) Experimental schematic showing progesterone treatment of wild type (WT) littermate control or IFN-L receptor (IFNLR) knock out mice, followed by sorting of EpCam + and CD45 + cells for single cell RNA sequencing. (F) UMAP projection showing uterine cells sorted using an EpCam gate. (G) Expression of the ISGs Ifi27l2a, Irf7, Isg15, Oas2, Oasl2 across EpCam + clusters from WT and IFNLR KO mice. (H) Volcano plot displaying differentially expressed genes from uterine luminal epithelial cells. (I) Top enriched GO term pathways for genes downregulated in uterine luminal epithelial cells from IFNLR KO mice, with Log 2 fold change values shown for differentially expressed genes in each highlighted pathway. (J) Working model. (B-D) Each dot represents an individual tissue from three biological replicates with mean with ± SEM. Significance determined by an unpaired Student’s t-test. * denote p-val <0.05 ** denote p-val <0.01.
    Ifn A/B, supplied by ImmunoTools, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ifn+b/ifn+c/pmc11244337__KONI_A_2377830_SM9147-9-7-8
    Average 90 stars, based on 1 article reviews
    ifn-a/b - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    (a) Schematic of laser-cut PDMS microwell array reversibly assembled on a polystyrene petri dish and workflow of enzymatically amplified silver metallization using Biotin-BSA and poly-HRP-SA. (b) Cell-phone image of silver metallized wells after assay. (c) Biotin-BSA dilution curve obtained from cell-phone image silver darkness quantification in ImageJ. (d) Assay stack for initial biotinyl tyramide signal amplification testing using biotinylated anti-IFN-γ as capture. (e) Dilution curve of silver darkness of increasing biotinylated anti-IFN-γ as target and 10 µg/mL, 1 µg/mL, and 0 µg/mL biotinyl tyramide. All assays were repeated three (n=3) times and fit lines are four-parameter logistic sigmoidal curves.

    Journal: bioRxiv

    Article Title: Inexpensive High-Throughput Multiplexed Cytokine Detection for Tuberculosis Diagnostics Using Amplified Enzymatic Metallization

    doi: 10.64898/2026.01.27.700981

    Figure Lengend Snippet: (a) Schematic of laser-cut PDMS microwell array reversibly assembled on a polystyrene petri dish and workflow of enzymatically amplified silver metallization using Biotin-BSA and poly-HRP-SA. (b) Cell-phone image of silver metallized wells after assay. (c) Biotin-BSA dilution curve obtained from cell-phone image silver darkness quantification in ImageJ. (d) Assay stack for initial biotinyl tyramide signal amplification testing using biotinylated anti-IFN-γ as capture. (e) Dilution curve of silver darkness of increasing biotinylated anti-IFN-γ as target and 10 µg/mL, 1 µg/mL, and 0 µg/mL biotinyl tyramide. All assays were repeated three (n=3) times and fit lines are four-parameter logistic sigmoidal curves.

    Article Snippet: Recombinant human IFN-γ protein (11725-HNAS), biotinylated anti-human IFN-γ antibody (11725-R209-B), anti-human IFN-γ antibody (11725-R238), HRP-conjugated anti-human IFN-γ antibody (11725-R209-H), recombinant human TNF-α protein (10602-HNAE), biotinylated anti-human TNF-α antibody (10602-MM08-B), and anti-human TNF-α antibody (10602-MM01) were obtained from SinoBiological.

    Techniques: Amplification

    (a) Schematic of immunoassay for cytokine detection. (b) Initial LOD optimization for the IFN-γ assay. (c-e) IFN-γ (n=2), IL-2 (n=5), TNF-α (n=2) dilution curves using recombinant cytokines (f-h) Correlation plots of ELISA absorbance values at 450 nm versus silver darkness values for IFN-γ (f), TNF-α (g), and IL-2 (h). All fit lines are four-parameter logistic sigmoidal curves.

    Journal: bioRxiv

    Article Title: Inexpensive High-Throughput Multiplexed Cytokine Detection for Tuberculosis Diagnostics Using Amplified Enzymatic Metallization

    doi: 10.64898/2026.01.27.700981

    Figure Lengend Snippet: (a) Schematic of immunoassay for cytokine detection. (b) Initial LOD optimization for the IFN-γ assay. (c-e) IFN-γ (n=2), IL-2 (n=5), TNF-α (n=2) dilution curves using recombinant cytokines (f-h) Correlation plots of ELISA absorbance values at 450 nm versus silver darkness values for IFN-γ (f), TNF-α (g), and IL-2 (h). All fit lines are four-parameter logistic sigmoidal curves.

    Article Snippet: Recombinant human IFN-γ protein (11725-HNAS), biotinylated anti-human IFN-γ antibody (11725-R209-B), anti-human IFN-γ antibody (11725-R238), HRP-conjugated anti-human IFN-γ antibody (11725-R209-H), recombinant human TNF-α protein (10602-HNAE), biotinylated anti-human TNF-α antibody (10602-MM08-B), and anti-human TNF-α antibody (10602-MM01) were obtained from SinoBiological.

    Techniques: Recombinant, Enzyme-linked Immunosorbent Assay

    (a) Schematic demonstrating the stimulation groups and controls. Dilution curves for IFN-γ (b-c), IL-2 (d-e), and TNF-α (f-g) in pooled LTB+ and LTB-clinical supernatant samples. Clinical samples consisted of NIL (negative control), Ag1, Ag2, and Mitogen (positive control) groups (n=2).

    Journal: bioRxiv

    Article Title: Inexpensive High-Throughput Multiplexed Cytokine Detection for Tuberculosis Diagnostics Using Amplified Enzymatic Metallization

    doi: 10.64898/2026.01.27.700981

    Figure Lengend Snippet: (a) Schematic demonstrating the stimulation groups and controls. Dilution curves for IFN-γ (b-c), IL-2 (d-e), and TNF-α (f-g) in pooled LTB+ and LTB-clinical supernatant samples. Clinical samples consisted of NIL (negative control), Ag1, Ag2, and Mitogen (positive control) groups (n=2).

    Article Snippet: Recombinant human IFN-γ protein (11725-HNAS), biotinylated anti-human IFN-γ antibody (11725-R209-B), anti-human IFN-γ antibody (11725-R238), HRP-conjugated anti-human IFN-γ antibody (11725-R209-H), recombinant human TNF-α protein (10602-HNAE), biotinylated anti-human TNF-α antibody (10602-MM08-B), and anti-human TNF-α antibody (10602-MM01) were obtained from SinoBiological.

    Techniques: Negative Control, Positive Control

    Individual participant silver darkness values for IFN-γ (a), IL-2 (b), and TNF-α (c) detection from NIL, Ag1, Ag2, and Mitogen samples of IGRA+ and IGRA-patients using a sample dilution of 1:10. Average of n=2 repeats was plotted for each sample.

    Journal: bioRxiv

    Article Title: Inexpensive High-Throughput Multiplexed Cytokine Detection for Tuberculosis Diagnostics Using Amplified Enzymatic Metallization

    doi: 10.64898/2026.01.27.700981

    Figure Lengend Snippet: Individual participant silver darkness values for IFN-γ (a), IL-2 (b), and TNF-α (c) detection from NIL, Ag1, Ag2, and Mitogen samples of IGRA+ and IGRA-patients using a sample dilution of 1:10. Average of n=2 repeats was plotted for each sample.

    Article Snippet: Recombinant human IFN-γ protein (11725-HNAS), biotinylated anti-human IFN-γ antibody (11725-R209-B), anti-human IFN-γ antibody (11725-R238), HRP-conjugated anti-human IFN-γ antibody (11725-R209-H), recombinant human TNF-α protein (10602-HNAE), biotinylated anti-human TNF-α antibody (10602-MM08-B), and anti-human TNF-α antibody (10602-MM01) were obtained from SinoBiological.

    Techniques:

    (A) Experimental schematic depicting isotype control (Iso) and a-IFN-L blocking antibody treatment (a-IFN-L) following progesterone administration in SPF or GF mice. (B) Quantification of uterine type 17 lymphoid cells shown as fold change in absolute cell number in progesterone treated SPF animals treated with a-IFN-L relative to Iso treated animals. (C, D) Quantification of absolute cell number of uterine (C) RORγT + γδT cells and (D) Th17 cells. (E) Experimental schematic showing progesterone treatment of wild type (WT) littermate control or IFN-L receptor (IFNLR) knock out mice, followed by sorting of EpCam + and CD45 + cells for single cell RNA sequencing. (F) UMAP projection showing uterine cells sorted using an EpCam gate. (G) Expression of the ISGs Ifi27l2a, Irf7, Isg15, Oas2, Oasl2 across EpCam + clusters from WT and IFNLR KO mice. (H) Volcano plot displaying differentially expressed genes from uterine luminal epithelial cells. (I) Top enriched GO term pathways for genes downregulated in uterine luminal epithelial cells from IFNLR KO mice, with Log 2 fold change values shown for differentially expressed genes in each highlighted pathway. (J) Working model. (B-D) Each dot represents an individual tissue from three biological replicates with mean with ± SEM. Significance determined by an unpaired Student’s t-test. * denote p-val <0.05 ** denote p-val <0.01.

    Journal: bioRxiv

    Article Title: Microbiota-dependent IFN-L controls uterine and placental immunity

    doi: 10.64898/2026.01.27.701820

    Figure Lengend Snippet: (A) Experimental schematic depicting isotype control (Iso) and a-IFN-L blocking antibody treatment (a-IFN-L) following progesterone administration in SPF or GF mice. (B) Quantification of uterine type 17 lymphoid cells shown as fold change in absolute cell number in progesterone treated SPF animals treated with a-IFN-L relative to Iso treated animals. (C, D) Quantification of absolute cell number of uterine (C) RORγT + γδT cells and (D) Th17 cells. (E) Experimental schematic showing progesterone treatment of wild type (WT) littermate control or IFN-L receptor (IFNLR) knock out mice, followed by sorting of EpCam + and CD45 + cells for single cell RNA sequencing. (F) UMAP projection showing uterine cells sorted using an EpCam gate. (G) Expression of the ISGs Ifi27l2a, Irf7, Isg15, Oas2, Oasl2 across EpCam + clusters from WT and IFNLR KO mice. (H) Volcano plot displaying differentially expressed genes from uterine luminal epithelial cells. (I) Top enriched GO term pathways for genes downregulated in uterine luminal epithelial cells from IFNLR KO mice, with Log 2 fold change values shown for differentially expressed genes in each highlighted pathway. (J) Working model. (B-D) Each dot represents an individual tissue from three biological replicates with mean with ± SEM. Significance determined by an unpaired Student’s t-test. * denote p-val <0.05 ** denote p-val <0.01.

    Article Snippet: Mice were also injected intraperitoneally with 2.25 mg/kg of anti-mouse IFN-L-2/3 antibody (MAB17892, R&D Systems) or rat IgG 2b isotype control antibody (clone MAB0061, R&D systems) as previously published , , .

    Techniques: Control, Blocking Assay, Knock-Out, RNA Sequencing, Expressing

    (A) Quantification of uterine ILC3 absolute cell number in SPF and GF animals treated with progesterone and Iso or a-IFN-L. Each dot represents an individual tissue from three biological replicates with mean ± SEM. Significance was determined by an unpaired Student’s t-test. (B) UMAP projection of CD45 + cells sorted from WT and IFNLR KO uteri. (C) Dot plot showing expression of Ifnar1 or Ifnlr in WT cells from the EpCam + and CD45 + library. (D, E) Dot plot showing marker gene expression for each cell type from the (D) EpCam + or (E) CD45 + library.

    Journal: bioRxiv

    Article Title: Microbiota-dependent IFN-L controls uterine and placental immunity

    doi: 10.64898/2026.01.27.701820

    Figure Lengend Snippet: (A) Quantification of uterine ILC3 absolute cell number in SPF and GF animals treated with progesterone and Iso or a-IFN-L. Each dot represents an individual tissue from three biological replicates with mean ± SEM. Significance was determined by an unpaired Student’s t-test. (B) UMAP projection of CD45 + cells sorted from WT and IFNLR KO uteri. (C) Dot plot showing expression of Ifnar1 or Ifnlr in WT cells from the EpCam + and CD45 + library. (D, E) Dot plot showing marker gene expression for each cell type from the (D) EpCam + or (E) CD45 + library.

    Article Snippet: Mice were also injected intraperitoneally with 2.25 mg/kg of anti-mouse IFN-L-2/3 antibody (MAB17892, R&D Systems) or rat IgG 2b isotype control antibody (clone MAB0061, R&D systems) as previously published , , .

    Techniques: Expressing, Marker, Gene Expression

    (A) Experimental schematic showing Iso or a-IFN-L treatment before and throughout intravaginal GBS colonization of nulliparous animals. (B-D) Quantification of GBS counts in (B) vaginal lavages from 1-6 dpa, (C) vaginal and (D) uterine tissue at 6 dpa. (E) Experimental schematic showing Iso or a-IFN-L treatment before and throughout intravaginal GBS infection of timed pregnant dams. (F) Number of implantation sites per litter in Iso or a-IFN-L treated GBS-infected pregnant dams. (G) Quantification of the fetus-to-placenta weight ratio in Iso or a-IFN-L treated GBS-infected pregnant dams at gd16.5. (H) Quantification of GBS counts in indicated tissues at 3 dpi. (I) Quantification of GBS counts in fetal liver at 3 dpi. (J) Graphical representation of fetal outcomes found in mock or GBS-infected Iso or a-IFN-L treated pregnant dams at gd16.5. (K) Working model. (B) Significance was determined by two-way ANOVA with Tukey’s multiple comparison test with mean ± SEM from three biological replicates. (C, D, G, H, I) Each dot represents an individual tissue from at least three biological replicates with mean ± SEM. (F) Each dot represents the total number of implantation sites per individual dam from at least three biological replicates with mean ± SEM. (C, D, F-I) Significance determined by an unpaired Student’s t-test. *** denote p-val<0.001, **** denote p-val<0.0001.

    Journal: bioRxiv

    Article Title: Microbiota-dependent IFN-L controls uterine and placental immunity

    doi: 10.64898/2026.01.27.701820

    Figure Lengend Snippet: (A) Experimental schematic showing Iso or a-IFN-L treatment before and throughout intravaginal GBS colonization of nulliparous animals. (B-D) Quantification of GBS counts in (B) vaginal lavages from 1-6 dpa, (C) vaginal and (D) uterine tissue at 6 dpa. (E) Experimental schematic showing Iso or a-IFN-L treatment before and throughout intravaginal GBS infection of timed pregnant dams. (F) Number of implantation sites per litter in Iso or a-IFN-L treated GBS-infected pregnant dams. (G) Quantification of the fetus-to-placenta weight ratio in Iso or a-IFN-L treated GBS-infected pregnant dams at gd16.5. (H) Quantification of GBS counts in indicated tissues at 3 dpi. (I) Quantification of GBS counts in fetal liver at 3 dpi. (J) Graphical representation of fetal outcomes found in mock or GBS-infected Iso or a-IFN-L treated pregnant dams at gd16.5. (K) Working model. (B) Significance was determined by two-way ANOVA with Tukey’s multiple comparison test with mean ± SEM from three biological replicates. (C, D, G, H, I) Each dot represents an individual tissue from at least three biological replicates with mean ± SEM. (F) Each dot represents the total number of implantation sites per individual dam from at least three biological replicates with mean ± SEM. (C, D, F-I) Significance determined by an unpaired Student’s t-test. *** denote p-val<0.001, **** denote p-val<0.0001.

    Article Snippet: Mice were also injected intraperitoneally with 2.25 mg/kg of anti-mouse IFN-L-2/3 antibody (MAB17892, R&D Systems) or rat IgG 2b isotype control antibody (clone MAB0061, R&D systems) as previously published , , .

    Techniques: Infection, Comparison

    (A) Experimental schematic showing Iso or a-IFN-L neutralizing antibody treatment before and throughout intravaginal GBS infection of timed pregnant dams. Maternal and neonatal outcomes were monitored through perinatal day 11. (B) Survival curve displaying maternal survival following GBS infection during pregnancy and through the first 11 days of the perinatal period. (C) Quantification of vaginal GBS burden in dams at perinatal day 11. (D) Quantification of litter size per individual dam at postnatal day 5. (E) Quantification of neonatal weight at postnatal day 5, 9 and 11. (F) Quantification of GBS CFU/mL in the neonatal liver, lung, brain, and intestine at postnatal day 11. Each dot represents an individual tissue with mean ± SEM. (G) Proportion of neonatal livers, lungs, brains, and intestines positive for GBS at postnatal day 11. (B-G) Three independent replicates were performed. (B) A log-rank test was performed to determine statistical significance. (C, F, G) An unpaired Student’s t-test was performed to determine statistical significance. (D) A one-way ANOVA with multiple comparisons was performed to determine statistical significance. (E) A two-way ANOVA with multiple comparisons was performed to determine statistical significance. *denote p-val <0.05.

    Journal: bioRxiv

    Article Title: Microbiota-dependent IFN-L controls uterine and placental immunity

    doi: 10.64898/2026.01.27.701820

    Figure Lengend Snippet: (A) Experimental schematic showing Iso or a-IFN-L neutralizing antibody treatment before and throughout intravaginal GBS infection of timed pregnant dams. Maternal and neonatal outcomes were monitored through perinatal day 11. (B) Survival curve displaying maternal survival following GBS infection during pregnancy and through the first 11 days of the perinatal period. (C) Quantification of vaginal GBS burden in dams at perinatal day 11. (D) Quantification of litter size per individual dam at postnatal day 5. (E) Quantification of neonatal weight at postnatal day 5, 9 and 11. (F) Quantification of GBS CFU/mL in the neonatal liver, lung, brain, and intestine at postnatal day 11. Each dot represents an individual tissue with mean ± SEM. (G) Proportion of neonatal livers, lungs, brains, and intestines positive for GBS at postnatal day 11. (B-G) Three independent replicates were performed. (B) A log-rank test was performed to determine statistical significance. (C, F, G) An unpaired Student’s t-test was performed to determine statistical significance. (D) A one-way ANOVA with multiple comparisons was performed to determine statistical significance. (E) A two-way ANOVA with multiple comparisons was performed to determine statistical significance. *denote p-val <0.05.

    Article Snippet: Mice were also injected intraperitoneally with 2.25 mg/kg of anti-mouse IFN-L-2/3 antibody (MAB17892, R&D Systems) or rat IgG 2b isotype control antibody (clone MAB0061, R&D systems) as previously published , , .

    Techniques: Infection